Clinical trials: Healthy Population
Immunization
Study of TAK-816 in Healthy Infants
The purpose of this study is to evaluate the efficacy (immunogenicity) of TAK-816 when administered to healthy Japanese infants as multiple subcutaneous doses.
- Trial name
- NCT01379846
- Testing
- TAK-816+ DPT-TAKEDA, ActHIB+ DPT-TAKEDA
- Where
- 22 sites in Japan
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Takeda
Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV)
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
Phase 1 clinical trial to evaluate the safety of RSV-1 and RSV-2 vaccines in healthy adults aged 19 to 80 years who have voluntarily given written consent to participate in this study.
- Trial name
- EuRSV (NCT06216093)
- Testing
- EuRSV
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Meningitis, Meningococcal, Rotavirus Infections
RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)
Primary objective: To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine.
- Trial name
- NCT00443846
- Testing
- RotaTeq®, NeisVac-C®
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatic Impairment, Healthy
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
To evaluate the effect of mild, moderate, or severe hepatic impairment on the pharmacokinetics (PK) of a single dose of 400 mg sotagliflozin (2 x 200-mg tablets) compared with healthy, demographically-matched subjects.
- Trial name
- NCT02471274
- Testing
- sotagliflozin
- Where
- 4 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution
- Trial name
- NCT02756624
- Testing
- AC-170 0.24%, AC-170 Vehicle
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- Nicox Ophthalmics, Inc.
Healthy Volunteer
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants. The main goal of the study is to compare the drug level achieved in the body, between the different…
- Trial name
- NCT05229562
- Testing
- BIIB122
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Subjects
A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers
This is a randomized, open-label, parallel-group, phase 1 study to evaluate the PD effect of AP301 capsule in healthy volunteers.
- Trial name
- NCT06100627
- Testing
- AP301
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alebund Pty Ltd
Healthy Volunteer
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
To evaluate the bioequivalence based on pharmacokinetics (PK) of a single 120 mg subcutaneous dose of denosumab administered to healthy volunteers using denosumab CP4 or denosumab CP2 drug products.
- Trial name
- NCT02053753
- Testing
- Denosumab CP4, Denosumab CP2
- Where
- 2 sites in United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State
This Phase I clinical study is to evaluate the safety/tolerability and pharmacokinetics of DA-1229_01(2.5/500 mg) at fasting state.
- Trial name
- NCT05739851
- Testing
- DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After)
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Drug Interaction
A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin
The primary purpose of this study is to determine whether the treatment with AZD1981 will affect the pharmacokinetics of pravastatin.
- Trial name
- NCT01254461
- Testing
- AZD1981, pravastatin
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects
The main purpose of this study is to assess the safety, tolerability and PK of AZD9742 after single IV doses.
- Trial name
- NCT01030224
- Testing
- AZD9742
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Insufficiency
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
The aim of the study is to assess whether renal impairment could affect fevipiprant pharmacokinetics (PK) to the extent that dosage adjustment is appropriate for this patient population.
- Trial name
- NCT03087942
- Testing
- QAW039, QAW39A, QAW39A2107
- Where
- 2 sites in United States, Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chikungunya Virus Infection
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults.
- Trial name
- NCT03483961
- Testing
- CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted
- Where
- 3 sites in United States
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Healthy
Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234
This Phase 1 study will be a double blind, third party open (ie, subject blind, investigator blind and Sponsor open), randomized, placebo controlled, single and multiple dose escalation study in healthy subjects, females of non…
- Trial name
- NCT02711462
- Testing
- PF-06687234
- Where
- Belgium
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects
This is a study comparing adalimumab Pfizer (PF-06410293) administered as a subcutaneous(SC) injection using a pre-filled syringe (PFS) or pre-filled pen in healthy adult subjects
- Trial name
- B538-05 (NCT02572245)
- Testing
- PF-06410293 PFS, PF-06410293 PFP
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
A Study of Multiple Oral Doses of IX-01 in Healthy Men
The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine how the body handles IX-01.
- Trial name
- NCT01994083
- Testing
- IX-01
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Ixchelsis Limited
Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR).
- Conditions
- Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers
- Trial name
- NCT06487845
- Testing
- BAY3283142
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers
This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
- Trial name
- NCT01959594
- Testing
- 3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer